ARWR
Arrowhead Pharmaceuticals, Inc.$70.17-3.44 (-4.67%)Prev Close$73.60·MCap$10.35B·P/E47.77·Vol1.16M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
20
$37.65M
◆
Net Activity
Net Seller
$37.65M
●
Active Insiders
9
last 12 mo
Over the past 12 months, insider activity at Arrowhead Pharmaceuticals, Inc. (ARWR) has been exclusively selling, with 0 insider purchases totaling $0.00 and 20 insider sales totaling $37.65M. The most recent insider transaction was by Apel Daniel Joseph (officer: Chief Financial Officer), who sold $934.3K worth of shares on Apr 24, 2026. Arrowhead Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $10.35B.
ARWR Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 24, 2026 | Apel Daniel Joseph | officer: Chief Financial Officer | Sell | 13,095 | $71.35 | $934.3K | 172,792 |
| Apr 24, 2026 | Hamilton James C | officer: Chief Medical Officer | Sell | 10,000 | $75.00 | $750.0K | 226,958 |
| Mar 9, 2026 | Hamilton James C | officer: Chief Medical Officer | Sell | 10,000 | $64.19 | $641.9K | 236,958 |
| Jan 5, 2026 | Hamilton James C | Chief Medical Officer | Sell | 40,164 | $63.11 | $2.53M | 0 |
| Jan 2, 2026 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 13,187 | $66.10 | $871.7K | 0 |
| Dec 31, 2025 | O'Brien Patrick | COO | Sell | 49,493 | $63.11 | $3.12M | 0 |
| Dec 29, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 51,726 | $69.13 | $3.58M | 0 |
| Dec 26, 2025 | Ferrari Mauro | Director | Sell | 7,530 | $70.00 | $527.1K | 0 |
| Dec 19, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 26,031 | $68.04 | $1.77M | 0 |
| Dec 19, 2025 | OLUKOTUN ADEOYE Y | Director | Sell | 10,000 | $67.66 | $676.6K | 0 |
| Dec 19, 2025 | Vakiener Victoria | Director | Sell | 10,040 | $67.68 | $679.5K | 0 |
| Dec 19, 2025 | Waddill William D. | Director | Sell | 8,367 | $67.65 | $566.0K | 0 |
| Dec 17, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 85,000 | $64.04 | $5.44M | 0 |
| Dec 12, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 184,298 | $67.00 | $12.35M | 0 |
| Dec 5, 2025 | PERRY MICHAEL S | Director | Sell | 16,250 | $61.03 | $991.7K | 0 |
| Nov 28, 2025 | Ferrari Mauro | Director | Sell | 8,750 | $56.39 | $493.4K | 0 |
| Oct 1, 2025 | Hamilton James C | Chief Medical Officer | Sell | 20,000 | $35.00 | $700.0K | 0 |
| Sep 12, 2025 | Hamilton James C | Chief Medical Officer | Sell | 15,000 | $30.00 | $450.0K | 0 |
| Sep 2, 2025 | Hamilton James C | Chief Medical Officer | Sell | 15,000 | $25.00 | $375.0K | 0 |
| Aug 13, 2025 | Hamilton James C | Chief Medical Officer | Sell | 10,000 | $20.00 | $200.0K | 0 |
| Apr 9, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 141,122 | $10.87 | $1.53M | 0 |
| Mar 13, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 51,425 | $15.07 | $775.0K | 0 |
| Mar 3, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 300,000 | $17.58 | $5.27M | 0 |
| Jan 23, 2025 | OLUKOTUN ADEOYE Y | Director | Sell | 959 | $21.00 | $20.1K | 0 |
| Jan 4, 2025 | Hamilton James C | Chief Discovery/Trans Medicine | Sell | 32,729 | $19.82 | $648.8K | 0 |
| Jan 4, 2025 | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 45,167 | $19.77 | $893.1K | 0 |
| Jan 4, 2025 | O'Brien Patrick | COO and General Counsel | Sell | 37,184 | $19.80 | $736.1K | 0 |
| Jan 2, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 11,520 | $19.05 | $219.5K | 0 |
| Dec 27, 2024 | OLUKOTUN ADEOYE Y | Director | Sell | 2,850 | $20.00 | $57.0K | 0 |
| Dec 23, 2024 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 12,563 | $19.59 | $246.1K | 0 |
| Dec 18, 2024 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 26,712 | $21.24 | $567.5K | 0 |
| Dec 16, 2024 | GIVEN DOUGLAS B | Director | Sell | 5,547 | $21.91 | $121.6K | 0 |
| Dec 16, 2024 | Vakiener Victoria | Director | Sell | 8,994 | $21.91 | $197.1K | 0 |
| Dec 16, 2024 | Waddill William D. | Director | Sell | 7,495 | $21.97 | $164.7K | 0 |
| Jul 2, 2024 | Oliver Tracie | Chief Commercial Officer | Sell | 9,394 | $25.28 | $237.5K | 0 |
| May 2, 2024 | Vakiener Victoria | Director | Sell | 1,799 | $23.31 | $41.9K | 0 |
| Apr 1, 2024 | Hamilton James C | Chief Discovery/Trans Medicine | Sell | 6,000 | $28.03 | $168.2K | 0 |
| Mar 18, 2024 | Lu Hongbo | Director | Buy | 3,000 | $27.66 | $83.0K | 0 |
| Mar 6, 2024 | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 40,000 | $35.19 | $1.41M | 0 |
| Jan 31, 2024 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 57,499 | $32.35 | $1.86M | 0 |
| Jan 12, 2024 | Hamilton James C | Chief Discovery/Trans Medicine | Sell | 7,940 | $36.89 | $292.9K | 0 |
| Jan 11, 2024 | Ferrari Mauro | Director | Sell | 3,147 | $38.06 | $119.8K | 0 |
| Jan 11, 2024 | GIVEN DOUGLAS B | Director | Sell | 2,911 | $38.06 | $110.8K | 0 |
| Jan 11, 2024 | Vakiener Victoria | Director | Sell | 4,720 | $38.10 | $179.8K | 0 |
| Jan 11, 2024 | Waddill William D. | Director | Sell | 3,934 | $38.07 | $149.8K | 0 |
| Jan 4, 2024 | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 16,104 | $35.27 | $567.9K | 0 |
| Jan 4, 2024 | Oliver Tracie | Chief Commercial Officer | Sell | 74 | $33.89 | $2.5K | 0 |
| Jan 4, 2024 | San Martin Javier | Chief Medical Officer | Sell | 8,303 | $35.26 | $292.8K | 0 |
| Jan 3, 2024 | Hamilton James C | Insider | Sell | 38,443 | $34.69 | $1.33M | 0 |
| Jan 3, 2024 | O'Brien Patrick | COO and General Counsel | Sell | 33,190 | $34.36 | $1.14M | 0 |
Showing 1–50 of 89
1 / 2
ARWR Insider Buying Activity
The following table shows recent insider purchases of Arrowhead Pharmaceuticals, Inc. (ARWR) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 18, 2024 | Lu Hongbo | Director | Buy | 3,000 | $27.66 | $83.0K | 0 |
ARWR Insider Selling Activity
The following table shows recent insider sales of Arrowhead Pharmaceuticals, Inc. (ARWR) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 24, 2026 | Apel Daniel Joseph | officer: Chief Financial Officer | Sell | 13,095 | $71.35 | $934.3K | 172,792 |
| Apr 24, 2026 | Hamilton James C | officer: Chief Medical Officer | Sell | 10,000 | $75.00 | $750.0K | 226,958 |
| Mar 9, 2026 | Hamilton James C | officer: Chief Medical Officer | Sell | 10,000 | $64.19 | $641.9K | 236,958 |
| Jan 5, 2026 | Hamilton James C | Chief Medical Officer | Sell | 40,164 | $63.11 | $2.53M | 0 |
| Jan 2, 2026 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 13,187 | $66.10 | $871.7K | 0 |
| Dec 31, 2025 | O'Brien Patrick | COO | Sell | 49,493 | $63.11 | $3.12M | 0 |
| Dec 29, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 51,726 | $69.13 | $3.58M | 0 |
| Dec 26, 2025 | Ferrari Mauro | Director | Sell | 7,530 | $70.00 | $527.1K | 0 |
| Dec 19, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 26,031 | $68.04 | $1.77M | 0 |
| Dec 19, 2025 | OLUKOTUN ADEOYE Y | Director | Sell | 10,000 | $67.66 | $676.6K | 0 |
| Dec 19, 2025 | Vakiener Victoria | Director | Sell | 10,040 | $67.68 | $679.5K | 0 |
| Dec 19, 2025 | Waddill William D. | Director | Sell | 8,367 | $67.65 | $566.0K | 0 |
| Dec 17, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 85,000 | $64.04 | $5.44M | 0 |
| Dec 12, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 184,298 | $67.00 | $12.35M | 0 |
| Dec 5, 2025 | PERRY MICHAEL S | Director | Sell | 16,250 | $61.03 | $991.7K | 0 |
| Nov 28, 2025 | Ferrari Mauro | Director | Sell | 8,750 | $56.39 | $493.4K | 0 |
| Oct 1, 2025 | Hamilton James C | Chief Medical Officer | Sell | 20,000 | $35.00 | $700.0K | 0 |
| Sep 12, 2025 | Hamilton James C | Chief Medical Officer | Sell | 15,000 | $30.00 | $450.0K | 0 |
| Sep 2, 2025 | Hamilton James C | Chief Medical Officer | Sell | 15,000 | $25.00 | $375.0K | 0 |
| Aug 13, 2025 | Hamilton James C | Chief Medical Officer | Sell | 10,000 | $20.00 | $200.0K | 0 |
| Apr 9, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 141,122 | $10.87 | $1.53M | 0 |
| Mar 13, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 51,425 | $15.07 | $775.0K | 0 |
| Mar 3, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 300,000 | $17.58 | $5.27M | 0 |
| Jan 23, 2025 | OLUKOTUN ADEOYE Y | Director | Sell | 959 | $21.00 | $20.1K | 0 |
| Jan 4, 2025 | Hamilton James C | Chief Discovery/Trans Medicine | Sell | 32,729 | $19.82 | $648.8K | 0 |
| Jan 4, 2025 | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 45,167 | $19.77 | $893.1K | 0 |
| Jan 4, 2025 | O'Brien Patrick | COO and General Counsel | Sell | 37,184 | $19.80 | $736.1K | 0 |
| Jan 2, 2025 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 11,520 | $19.05 | $219.5K | 0 |
| Dec 27, 2024 | OLUKOTUN ADEOYE Y | Director | Sell | 2,850 | $20.00 | $57.0K | 0 |
| Dec 23, 2024 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 12,563 | $19.59 | $246.1K | 0 |
| Dec 18, 2024 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 26,712 | $21.24 | $567.5K | 0 |
| Dec 16, 2024 | GIVEN DOUGLAS B | Director | Sell | 5,547 | $21.91 | $121.6K | 0 |
| Dec 16, 2024 | Vakiener Victoria | Director | Sell | 8,994 | $21.91 | $197.1K | 0 |
| Dec 16, 2024 | Waddill William D. | Director | Sell | 7,495 | $21.97 | $164.7K | 0 |
| Jul 2, 2024 | Oliver Tracie | Chief Commercial Officer | Sell | 9,394 | $25.28 | $237.5K | 0 |
| May 2, 2024 | Vakiener Victoria | Director | Sell | 1,799 | $23.31 | $41.9K | 0 |
| Apr 1, 2024 | Hamilton James C | Chief Discovery/Trans Medicine | Sell | 6,000 | $28.03 | $168.2K | 0 |
| Mar 6, 2024 | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 40,000 | $35.19 | $1.41M | 0 |
| Jan 31, 2024 | Anzalone Christopher Richard | Chief Executive Officer | Sell | 57,499 | $32.35 | $1.86M | 0 |
| Jan 12, 2024 | Hamilton James C | Chief Discovery/Trans Medicine | Sell | 7,940 | $36.89 | $292.9K | 0 |
| Jan 11, 2024 | Ferrari Mauro | Director | Sell | 3,147 | $38.06 | $119.8K | 0 |
| Jan 11, 2024 | GIVEN DOUGLAS B | Director | Sell | 2,911 | $38.06 | $110.8K | 0 |
| Jan 11, 2024 | Vakiener Victoria | Director | Sell | 4,720 | $38.10 | $179.8K | 0 |
| Jan 11, 2024 | Waddill William D. | Director | Sell | 3,934 | $38.07 | $149.8K | 0 |
| Jan 4, 2024 | Myszkowski Kenneth Allen | Chief Financial Officer | Sell | 16,104 | $35.27 | $567.9K | 0 |
| Jan 4, 2024 | Oliver Tracie | Chief Commercial Officer | Sell | 74 | $33.89 | $2.5K | 0 |
| Jan 4, 2024 | San Martin Javier | Chief Medical Officer | Sell | 8,303 | $35.26 | $292.8K | 0 |
| Jan 3, 2024 | Hamilton James C | Insider | Sell | 38,443 | $34.69 | $1.33M | 0 |
| Jan 3, 2024 | O'Brien Patrick | COO and General Counsel | Sell | 33,190 | $34.36 | $1.14M | 0 |
ARWR Insiders
Similar Stocks to ARWR
VRTX
Vertex Pharmaceuticals Incorporated
$429.47+0.81%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.44-1.64%
$41.24B
INSM
Insmed Incorporated
$135.11-0.64%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.62+9.92%
$29.51B
UTHR
United Therapeutics Corporation
$566.69+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.16-3.17%
$21.42B
RPRX
Royalty Pharma plc
$49.40-0.50%
$21.20B